drugset / Trial / NCT02045264

Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers

NCT02045264

Phase 1 Completed 12 enrolled Shire
NaSingle-groupOpen-labelTreatment

Summary

This is a single-dose study to evaluate the pharmacokinetics, safety, and tolerability of icatibant administered to adult Japanese subjects.

Timeline

Start
2014-02-21
Primary completion
2014-02-27
Completion
2014-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Icatibant Peptide 30 mg Subcutaneous

Indications